Daily Endocrinology Research Analysis
Three impactful endocrinology studies stood out today: an international guideline endorsing burosumab for adults with X-linked hypophosphatemia, a high-resolution immune atlas of pituitary neuroendocrine tumors revealing endocrine-driven immune states and combination PD-1 blockade potential, and a long-term cohort suggesting islet transplantation reduces mortality and major complications in type 1 diabetes without raising cancer risk.
Summary
Three impactful endocrinology studies stood out today: an international guideline endorsing burosumab for adults with X-linked hypophosphatemia, a high-resolution immune atlas of pituitary neuroendocrine tumors revealing endocrine-driven immune states and combination PD-1 blockade potential, and a long-term cohort suggesting islet transplantation reduces mortality and major complications in type 1 diabetes without raising cancer risk.
Research Themes
- Evidence-based endocrine therapy guidelines (rare bone disease)
- Tumor immune microenvironment in neuroendocrine oncology
- Long-term outcomes of cell-based therapy in type 1 diabetes
Selected Articles
1. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline.
An international, GRADE-based guideline for adult XLH recommends burosumab over no therapy for those with fractures/pseudofractures and suggests burosumab over conventional phosphate/active vitamin D in many scenarios. Diagnosis integrates clinical assessment with confirmation of renal phosphate wasting; PHEX variants are confirmatory but not required.
Impact: This guideline synthesizes the highest-level evidence with GRADE and provides actionable, consensus recommendations likely to standardize and improve adult XLH care globally.
Clinical Implications: Prefer burosumab in adults with XLH (especially with fractures/pseudofractures), implement multidisciplinary care, and use a structured diagnostic algorithm centered on renal phosphate wasting; use conventional therapy when burosumab is unavailable.
Key Findings
- Burosumab is strongly recommended over no therapy in adults with XLH and fractures/pseudofractures (GRADEd).
- Burosumab is suggested over conventional therapy even without fractures (conditional, GRADEd).
- Diagnosis relies on clinical assessment plus confirmation of renal phosphate wasting; PHEX variants confirm but are not mandatory.
Methodological Strengths
- Two systematic reviews with GRADE methodology underpin key recommendations
- Consensus process with 43 experts, methodologists, a patient partner, and multi-society endorsement
Limitations
- Evidence gaps necessitated Non-GRADED recommendations in some areas
- Limited head-to-head and long-term comparative data for adult outcomes and safety
Future Directions: Prospective registries and RCTs comparing burosumab vs conventional therapy, long-term outcomes (skeletal, renal, QoL), and cost-effectiveness analyses.
PURPOSE: An international working group (IWG) consisting of experts in X-linked hypophosphatemia (XLH) developed global guidelines providing a comprehensive, evidence-based approach to XLH diagnosis, management, and monitoring. METHODS: The IWG, consisting of 43 members as well as methodologists and a patient partner, conducted 2 systematic reviews (SRs) and narrative reviews to address key areas. The SRs addressed the impact of burosumab compared to conventional therapy (phosphate and active vitamin D) or no therapy on patient-important outcomes in adults. They also evaluated conventional therapy compared to no therapy. GRADE methodology was applied to evaluate the certainty of evidence. Non-GRADED recommendations were made in the presence of insufficient evidence to conduct SRs. These guidelines have been reviewed and endorsed by several medical and patient societies and organizations. RESULTS: The diagnosis of XLH is based on integrating clinical evaluation, laboratory findings confirming renal phosphate wasting (following exclusion of conditions mimicking XLH), and skeletal imaging. Fibroblast growth factor 23 measurement and DNA analysis are of value in the diagnosis, if available. Pathogenic or likely pathogenic variants in the PHEX gene are confirmatory but not necessary for the diagnosis. Management requires a multidisciplinary team knowledgeable and experienced in XLH. Effective medical therapy with burosumab can improve fracture and pseudofracture healing. MAIN CONCLUSION: In adults with XLH and fractures or pseudofractures, burosumab is recommended over no therapy (strong recommendation, GRADEd). Additionally, burosumab is suggested as the preferred treatment compared to conventional therapy (conditional recommendation, GRADEd) in the absence of fractures or pseudofractures. If burosumab is not available, symptomatic adults should be treated with conventional therapy (Non-GRADEd recommendation).
2. Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication.
Mass cytometry across 56 pitNETs reveals that hormone secretion status governs immune composition: functioning tumors are T cell–enriched with immunosuppressive markers (CD38, PD-1, PD-L1), correlating with shorter PFS. In primary cultures, combining PD-1 blockade with tumor-targeted therapy synergistically increases apoptosis, induces cell-cycle arrest, and suppresses hormone secretion.
Impact: Provides a comprehensive immune atlas linking endocrine function to immunobiology and proposes a rational combination (PD-1 blockade plus targeted therapy) with functional validation in patient-derived cells.
Clinical Implications: Suggests stratifying pitNETs by hormone secretion and immune markers to guide immunotherapy; supports clinical testing of PD-1 blockade combined with tumor-targeted therapies in functioning pitNETs.
Key Findings
- PitNETs show sparse immune infiltration overall; macrophages and T cells dominate.
- Functioning pitNETs are T cell–enriched with high CD38, PD-1, and PD-L1 expression, linked to shorter progression-free survival.
- PD-1 blockade combined with tumor-targeted therapy synergistically enhances apoptosis, induces cell-cycle arrest, and suppresses hormone secretion in primary cultures.
Methodological Strengths
- High-dimensional mass cytometry profiling of 97,418 immune cells across 56 tumors
- Integration of immune atlas with functional assays in patient-derived primary cell cultures
Limitations
- Observational profiling without in vivo clinical trial validation
- Cohort size may not capture all pitNET subtypes; ex vivo synergy requires clinical confirmation
Future Directions: Prospective trials testing PD-1 blockade plus targeted agents in functioning pitNETs; development of predictive biomarkers and spatial multi-omics to refine patient selection.
Whether the tumor microenvironment is shaped by endocrine hormone secretion, as well as its cellular heterogeneity and therapeutic implications in pituitary neuroendocrine tumors (pitNETs), remains poorly understood. We demonstrate that pitNETs exhibit a sparse immune infiltration. Mass cytometry of 97,418 immune cells from 56 pitNETs establishes a high-resolution atlas, with macrophages and T cells comprising the predominant populations. Hormone secretion status dictates the immune composition and cellular phenotype. Functioning pitNETs are enriched with T cells, with robust expression of immune-suppressive markers CD38, programmed death (PD)-1, and PD-L1. The lymphoid-enriched microenvironment is associated with shorter progression-free survival in patients with pitNETs. Integrating PD-1 blockade with tumor-targeted therapy in functioning pitNETs demonstrates synergistic efficacy with enhanced apoptosis, induces cell-cycle arrest, and suppresses hormone secretion using patient-derived primary cell cultures. Altogether, our findings provide an extended resource on the cellular and functional heterogeneity of the pitNET immune microenvironment and offer a conceptual framework for rational therapeutic strategies.
3. Impact of Islet Transplantation on Diabetes Complications and Mortality in Patients Living With Type 1 Diabetes.
In a propensity-matched, multicenter cohort with >10-year follow-up, islet transplantation was associated with fewer major complications versus matched T1D controls: IT alone reduced composite outcomes (HR 0.39) driven by lower mortality (HR 0.22), and IT after kidney transplant reduced dialysis (HR 0.19). No increase in cancer risk was observed despite chronic immunosuppression.
Impact: Provides rare long-term, hard-outcome evidence for islet transplantation in unstable T1D, addressing mortality and macrovascular/renal complications alongside safety (cancer).
Clinical Implications: Supports referral of unstable T1D patients for islet transplantation consideration; informs counseling on long-term benefits and the lack of increased cancer risk under immunosuppression.
Key Findings
- ITA recipients had a 61% lower risk of composite outcomes vs matched T1D controls (HR 0.39; 95% CI 0.21–0.71).
- Mortality was markedly reduced in ITA (HR 0.22), and dialysis risk reduced in IAK (HR 0.19).
- No significant increase in cancer incidence in either ITA or IAK despite immunosuppression.
Methodological Strengths
- Propensity score–matched multicenter cohorts with >10 years of follow-up
- Hard clinical outcomes (mortality, dialysis, cardiovascular/cerebrovascular events) and cancer surveillance
Limitations
- Retrospective design susceptible to selection and residual confounding
- Recipient sample sizes are modest, particularly for IAK; generalizability beyond French care context uncertain
Future Directions: Prospective registries and randomized evaluations of immunosuppression regimens, cost-effectiveness, quality of life, and comparison with advanced technologies (e.g., automated insulin delivery).
OBJECTIVE: This study aimed to evaluate the impact of islet transplantation (IT) on diabetes complications, death, and cancer incidence. RESEARCH DESIGN AND METHODS: This retrospective, multicenter, cohort study included patients from three IT clinical trials (intervention group) and from the French health insurance claims database Système National des Données de Santé (SNDS) (control group). Two cohorts of IT recipients were analyzed: IT recipients after kidney transplantation (IAK) and IT recipients alone (ITA). They were matched with patients living with type 1 diabetes (T1D) from the SNDS using a propensity score. The primary outcome was a composite criterion including death, dialysis, amputation, nonfatal stroke, nonfatal myocardial infarction, and transient ischemic attack. The secondary outcome was cancer. Hazard ratio (HRs) and P values were obtained using Cox proportional hazards analysis and log-rank test, respectively. RESULTS: The study included 61 ITA recipients matched to 610 T1D control patients and 45 IAK recipients matched to 45 T1D control patients over a median follow-up period >10 years. Compared with T1D control patients, ITA and IAK recipients had a lower composite outcome risk (HR 0.39 [95% CI 0.21-0.71; P = 0.002] and 0.52 [0.30-0.88; P = 0.014], respectively) that seemed driven by reduced mortality (0.22 [0.09-0.54]; P < 0.001) for ITA and reduced dialysis (0.19 [0.07-0.50]; P < 0.001) for IAK. Both groups showed no significant changes in cancer risk. CONCLUSIONS: This study suggests long-term benefits of IT on diabetes-related outcomes. Furthermore, despite the use of immunosuppressive drugs following IT, we observed no significant increase in the risk of cancer. Altogether, these findings highlight a favorable risk-benefit ratio of IT in treating patients with unstable T1D.